Tagged with Pfizer

Pfizer The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is to devise different sustainable business models that allow for more affordable medicines, and how Pfizer must crack the emerging market…

Pfizer The country manager of Pfizer Morocco talks about the likelihood of Morocco becoming an African hub and why Pfizer is at the perfect size to play a key part in such a process, as well as how the country’s price decree hurt the multinational corporations.   Having been elected head of MIS…

Pfizer Edgardo Vázquez, Pfizer’s country manager for the Argentina Region, discusses the company’s investment strategies across their newly established business units and a few of the unique challenges presented by the Argentinean market.   How have Pfizer’s goals for Argentina changed over the last few years, and what is your strategy…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…

Contract Manufacturing Lilly set up in Ireland three decades ago by purchasing a farm. In its early days, the operation produced intermediaries for small-molecule drugs. Nearby, Pfizer was manufacturing citric acid for soft drinks. The country was a fledgling industrial economy that was still mostly reliant on sectors like agriculture and fishing.…

Pfizer Ireland You noted that, in the ‘old days’, the pharma business had the following characteristics: first of all, it was a molecule-driven business, fueled by blockbuster medicines that met robust medical need; second, there was a promising pipeline of medical advances; third, there were less budgetary constraints, and more localized decision…

Pfizer Austria Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in Austria, just behind Novartis, which includes its subsidiaries Sandoz, Hexal, and 1A Pharma. Our focus clearly lies on country customer…

Pfizer Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to provide a much more comprehensive portfolio and meet more patient needs in the country. It also opened new therapeutic areas…

Pfizer South Africa Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed as a country head for Pfizer’s local operations. What were the good and challenging issues you had to contend with…

Pfizer Serbia Pfizer is increasingly interested in emerging markets, with a focus very much on Latin America and Asia. Given this, why is Serbia exciting for Pfizer today? Serbia is interesting for most multinational companies, firstly because of the county’s geographic location, and secondly because of the relatively high population for the…

Pfizer Chile Last year Pfizer consolidated its position as the world´s largest global pharmaceutical company by acquiring Wyeth, of which you were previously the General Manager here in Chile. Given your privileged position as head of the combined company, how would you evaluate the integration of the two companies in Chile, and…

Pfizer Indonesia Pfizer has been one of the earliest believers in the Indonesian market, establishing its presence since 1969. As the number one MNC in Indonesia, how would you assess the current landscape for global research based companies in Indonesia? Although pharmaceutical products are shifting toward generics worldwide, what seems to be…